DOCKET NO.: IBIS-0007



PATENT

IN THE UNITED STATES PA ENT AND TRADEMARK OFFICE

RECEIVED

DEC 1 5 1999

David J. Ecker et al.

In Re Application of:

Group Art Unit: 1618 TECH CENTER 1600/2900

Serial No.: 09/076,404

Filing Date: May 12, 1998

Examiner: M. Garcia

MODULATION OF MOLECULAR INTERACTION SITES ON RNA AND

OTHER BIOMOLECULES

DATE OF DEPOSIT: 10 December 1899

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS,

WASHINGTON, DC 20231

REGISTRATION NO.: 38,534

Assistant Commissioner for Patents Washington DC 20231

Dear Sir:

For:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

 \boxtimes

In accordance with §1.97(b), since this Information Disclosure Statement is being

filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

	In accordance with §1.129(a), this Information Disclosure Statement is being
	filed in connection with \Box the first or \Box second After Final Submission,
	therefore:
	☐ Certification in Accordance with §1.97(e) is attached; or
	\square The fee of \$240.00 as set forth in \$1.17(p) is attached.
	In accordance with §1.97(c), this Information Disclosure Statement is being filed
	after the period set forth in \$1.97(b) above but before the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311, therefore: Certification in Accordance with \$1.97(e) is attached; or
	The fee of $$240.00$ as set forth in $$1.17(p)$ is attached.
	In accordance with §1.97(d), this Information Disclosure Statement is being filed
	after the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with \$1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in \$1.17(i)(1).
\boxtimes	Copies of each of the references listed on the attached Form PTO-1449 are
	enclosed herewith.
	Copies of references listed on the attached Form PTO-1449 are enclosed herewith
	EXCEPT THAT:
	☐ In view of the voluminous nature of references [list as appropriate]. and
	the likelihood that these references are available to the Examiner, copies

In accordance with §1.98(d), copies of the following references listed on
the attached Form PTO-1449 are not enclosed herewith because they were
previously cited by or submitted to the U.S. Patent and Trademark Office
in patent application(s) for which a claim for priority under 35
U.S.C.§120 have been made in the instant application:
Copies of references [list as appropriate] listed on the attached Form
PTO-1449 were previously cited by or submitted to the Patent and
Trademark Office in prior application Serial No. , filed .
☐ If any of the foregoing publications are not available to the
Examiner, Applicant will endeavor to supply copies at the
Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: 10 December 1999

Paul K. Legaard

Registration No. 38,534

WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP One Liberty Place - 46th Floor Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 1997 WWKMN